SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 19.54 |
| Enterprise Value ($M) | 30.79 |
| Book Value ($M) | -13.47 |
| Book Value / Share | -0.47 |
| Price / Book | -1.45 |
| NCAV ($M) | -15.47 |
| NCAV / Share | -0.54 |
| Price / NCAV | -1.26 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -4.43 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.16 |
| Current Ratio | 0.17 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 3.26 |
| Assets | 5.25 |
| Liabilities | 18.73 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 4.99 | 45.79 | |
| 13D/A | Rafael Holdings, Inc. | 49.00 | 5.13 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 283 | 6,247 | 4.53 | |
| 1,398 | 12,833 | 10.89 | |
| 5,451 | 18,208 | 29.94 | |
| 4,508 | 19,410 | 23.23 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CYCC – Cyclacel Pharmaceuticals, Inc. | CYCN – Cyclerion Therapeutics, Inc. |
| CYRX – Cryoport, Inc. | DARE – Daré Bioscience, Inc. |
| DERM – Journey Medical Corporation |
Financial data and stock pages provided by
Fintel.io